Amyloid-beta clearance in Alzheimer's disease
Strong evidence continues to accumulate indicating that amyloid-beta (Aß) is a central part of Alzheimer's disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aß are of great interest in understanding AD pathogene...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Frontiers Media SA
2015
|
| Series: | Frontiers Research Topics
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_40785 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2015 xx |||||o ||| 0|eng d | ||
| 020 | |a 978-2-88919-443-8 | ||
| 020 | |a 9782889194438 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3389/978-2-88919-443-8 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a PSAN |2 bicssc | |
| 100 | 1 | |a Robert Marr |4 auth | |
| 700 | 1 | |a Eliezer Masliah |4 auth | |
| 245 | 1 | 0 | |a Amyloid-beta clearance in Alzheimer's disease |
| 260 | |b Frontiers Media SA |c 2015 | ||
| 300 | |a 1 electronic resource (111 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Frontiers Research Topics | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Strong evidence continues to accumulate indicating that amyloid-beta (Aß) is a central part of Alzheimer's disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aß are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aß clearance in AD. The topics covered include proteases that degrade Aß and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Neurosciences |2 bicssc | |
| 653 | |a amyloid-beta | ||
| 653 | |a Signal Transduction | ||
| 653 | |a Proteases | ||
| 653 | |a LDL receptors | ||
| 653 | |a Clearance | ||
| 653 | |a Alzheimer's disease | ||
| 856 | 4 | 0 | |a www.oapen.org |u http://journal.frontiersin.org/researchtopic/2235/amyloid-beta-clearance-in-alzheimers-disease |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/40785 |7 0 |z DOAB: description of the publication |